{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:18:39Z","timestamp":1777025919702,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ejphar.2016.06.016","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T06:43:33Z","timestamp":1466059413000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo"],"prefix":"10.1016","volume":"788","author":[{"given":"Sung-Ho","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunsoo","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kyung","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. Hwan","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dal-Mi","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junghyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Mee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Joo","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.06.016_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.clinthera.2015.12.020","article-title":"Pharmacokinetic and pharmacodynamic effects of multiple-dose administration of omarigliptin, a once-weekly dipeptidyl peptidase-4 Inhibitor, in obese participants with and without type 2 diabetes mellitus","volume":"38","author":"Addy","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2016.06.016_bib2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.06.016_bib3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2165\/11591400-000000000-00000","article-title":"Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences","volume":"71","author":"Baetta","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2016.06.016_bib4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1463-1326.2008.00860.x","article-title":"Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited","volume":"10","author":"Burkey","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2016.06.016_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/sj.clpt.6100156","article-title":"Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents","volume":"81","author":"Cefalu","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2016.06.016_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/diabetes.52.2.365","article-title":"Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy","volume":"52","author":"De Leon","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.06.016_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2016.06.016_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.06.016_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2337\/diab.37.6.667","article-title":"Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM","volume":"37","author":"DeFronzo","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.06.016_bib10","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2337\/dc08-1035","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study","volume":"31","author":"DeFronzo","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2016.06.016_bib11","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2016.06.016_bib12","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1210\/en.2003-0323","article-title":"Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets","volume":"144","author":"Farilla","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2016.06.016_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/17425255.2014.907274","article-title":"The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]","volume":"10","author":"Filippatos","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2016.06.016_bib14","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1210\/jc.2006-1009","article-title":"Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes","volume":"91","author":"Herman","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.06.016_bib15","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.clinthera.2011.06.005","article-title":"Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients","volume":"33","author":"Horie","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejphar.2016.06.016_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2015.04.055","article-title":"Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy","volume":"761","author":"Jung","year":"2015","journal-title":"Eur. J. Pharmcol."},{"key":"10.1016\/j.ejphar.2016.06.016_bib17","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1517\/14656566.2015.1099630","article-title":"First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus","volume":"16","author":"Kaku","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2016.06.016_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1185\/030079908X261069","article-title":"Sitagliptin, a DPP\u22124 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials","volume":"24","author":"Karasik","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2016.06.016_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/jm0493156","article-title":"(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes","volume":"48","author":"Kim","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.06.016_bib20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s12272-013-0171-x","article-title":"Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry","volume":"36","author":"Kim","year":"2013","journal-title":"Arch. Pharmacal Res."},{"key":"10.1016\/j.ejphar.2016.06.016_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1042\/CS20090047","article-title":"Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition","volume":"118","author":"Kirby","year":"2010","journal-title":"Clin. Sci. Lond."},{"key":"10.1016\/j.ejphar.2016.06.016_bib22","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9","volume":"54","author":"Lankas","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.06.016_bib23","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1007\/s40265-015-0496-5","article-title":"Evogliptin: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2016.06.016_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)\u2013role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejphar.2016.06.016_bib25","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.06.016_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1006\/bbrc.2001.4999","article-title":"Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats","volume":"284","author":"Nagakura","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2016.06.016_bib27","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejphar.2016.06.016_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1267\/ahc.13012","article-title":"Effect of regular exercise on the histochemical changes of d-galactose-induced oxidative renal injury in high-fat diet-fed rats","volume":"46","author":"Park","year":"2013","journal-title":"Acta Histochem. Cytochem."},{"key":"10.1016\/j.ejphar.2016.06.016_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/17460441.2011.588695","article-title":"Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview","volume":"6","author":"Parsa","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejphar.2016.06.016_bib30","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/endo.141.12.7806","article-title":"Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats","volume":"141","author":"Perfetti","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2016.06.016_bib31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.52.3.741","article-title":"Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats","volume":"52","author":"Pospisilik","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.06.016_bib32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1463-1326.2010.01303.x","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes","volume":"12","author":"Rhee","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2016.06.016_bib33","unstructured":"Rhee, E.J., Min, K.W., Jang, H.C., Chung, C.H., Nam-Goong, I.S., Bae, H.Y., Baik, S.H., Shivane, V.K., Sosale, A.R., Dharmalingam, M., Gandhi, P., Gupta, S.K., Ahn, J.Y., Bang, K.S., Lee, M.K., 2013. Gemigliptin added to ongoing metformin therapy provides sustained glycaemic control over 52 weeks and was well tolerated in patients with type 2 diabetes. In: Presented at 49th EASD Annual Meeting. 23\u201327 September. Barcelona, Spain."},{"key":"10.1016\/j.ejphar.2016.06.016_bib34","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2337\/dc12-0199","article-title":"Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition","volume":"35","author":"Rizzo","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2016.06.016_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/dc07-1616","article-title":"Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance","volume":"31","author":"Rosenstock","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2016.06.016_bib36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40261-014-0184-3","article-title":"Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects","volume":"34","author":"Shin","year":"2014","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejphar.2016.06.016_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13098-015-0047-y","article-title":"High-fat diet feeding significantly attenuates anagliptin-induced regeneration of islets of Langerhans in streptozotocin-induced diabetic mice","volume":"7","author":"Shinjo","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2016.06.016_bib38","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/dom.12292","article-title":"Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444)","volume":"16","author":"Shon","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2016.06.016_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.49.5.741","article-title":"Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas","volume":"49","author":"Stoffers","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2016.06.016_bib40","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm030091l","article-title":"1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties","volume":"46","author":"Villhauer","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.06.016_bib41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2210-12-2","article-title":"Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor","volume":"12","author":"Wang","year":"2012","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.ejphar.2016.06.016_bib42","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00125-002-0828-3","article-title":"Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db\/db mice","volume":"45","author":"Wang","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2016.06.016_bib43","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2016.06.016_bib44","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916303752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916303752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T02:23:46Z","timestamp":1536632626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916303752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":44,"alternative-id":["S0014299916303752"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.06.016","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}